Transcode Therapeutics, Inc. (RNAZ): Nasdaq/NYSE listing notice — TransCode receives Nasdaq delisting notice; equity below $2.5M requirement

Transcode Therapeutics, Inc.

Nasdaq rejected TransCode's compliance plan to regain stockholders' equity of at least $2.5M.
Company intends to appeal to Nasdaq Hearings Panel by August 2, 2023; appeal stays delisting pending hearing.
If no appeal, common stock (RNAZ) will be suspended from trading on Nasdaq at open on August 4, 2023.
Non-compliance initially disclosed on May 16, 2023; compliance plan submitted June 30 and supplemented July 24.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

July 26, 2023, the Company received a Delisting Determination Letter from the Staff advising the Company that the Staff had determined not to accept the Company’s Compliance Plan, and that the Company’s request for an extension had been denied. If, in accordance with Nasdaq Listing Rule 5815(a), the Company requests a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s decision, such request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. If the Company does not request a hearing t

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-085347

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.